Navigation Links
Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015
Date:1/30/2013

BURLINGTON, Mass., Jan. 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts the launch of new agents positioned for the treatment of both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) through 2018. According to two Niche Markets and Rare Diseases reports, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, novel targeted therapies hold the most promise for improving outcomes for patients with acute leukemia. Interviewed experts are enthusiastic about the potential of Amgen/MicroMet's blinatumomab–a first-in-class bispecific T-cell engager–for the treatment of ALL. Experts also highlight the potential of Ambit Biosciences/Astellas Pharma's quizartinib in AML: quizartinib will be the first agent that will be targeted to a specific AML sub-population, those patients with mutations in FLT3. However, clinical benefit in relapsed/refractory patients that do not harbor mutations in FLT3 suggests that uptake of the drug in a wider population is anticipated.

"The late-stage acute leukemia pipeline has shown a lot of promise lately, and experts are excited at the prospect of having more targeted therapies available to add to traditional chemotherapy options," said Decision Resources Therapy Leader Joanne Graham , Ph.D. "New formulations of existing chemotherapies will also play a role in the late-stage pipeline. Despite the promise of novel targeted drugs, there is no doubt that the future treatment of acute leukemia will continue to rely heavily on chemotherapies."These reports also find that, despite the launch of several new agents throughout the forecast period, there are still high levels of unmet need in the acute leukemia space, especially for treatments that provide improved efficacy outcomes for, and are less toxic to older patients, as well as treatments tailored towards currently underserved populations, such as T-cell leukemia.

"Acute lymphoblastic leukemia is the most commonly diagnosed cancer in children but only accounts for a minority of adult leukemias," said Dr. Graham. "The prognosis for adult patients is discouraging, with an overall adult survival rate of approximately 40 percent, compared with 80 percent in children. As this demographic grows, so does the need for treatments directed at older and adult patients whose disease is often more aggressive."

About Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia are offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The reports provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources  Decision Resources GroupAllison Thrower

Liz Marshall781-993-2604

781-993-2563athrower@dresourcesgroup.com 

emarshall@dresourcesgroup.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
2. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
3. Study Delivers Investment Benchmarks across Key New Product Launch Activities in Pharmaceutical Sector
4. Heritage Provider Network, UCLA and Open mHealth announce the launch of $100,000 mobile apps health prize challenge
5. Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
6. New Website IVT Network Launches Today for Validation and Compliance Professionals
7. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
8. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
9. Sequent Medical, Inc. Launches VIA Microcatheter
10. Producer Austin Chapman Reaches Millions with Inspiring Story on Hearing Loss; Launches Contest in Partnership with Phonak
11. NASBE Launches Epinephrine Policy Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
Breaking Medicine News(10 mins):